Breaking News, Collaborations & Alliances

AbbVie, Tizona in Strategic Immunotherapy Alliance

To develop and commercialize CD39-targeted therapeutics, including TTX-030, a first-in-class antibody for the treatment of cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie and Tizona Therapeutics, Inc. have entered into a global, strategic collaboration to develop and commercialize CD39-targeted therapeutics, including TTX-030, a first-in-class antibody for the treatment of cancer.     The ATP-adenosine, a key immune regulatory switch in the tumor microenvironment (TME) controlls the inflammatory and suppressive activities of immune cells. CD39 is the enzyme responsible for the initial steps in the conversion of immune stimulatory extracellular ATP to imm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters